



## Antibiotic Therapy for *Clostridioides difficile* Infections

Guest Editors:

**Dr. P. Brandon Bookstaver**

College of Pharmacy, University  
of South Carolina, Columbia, SC  
29208, USA

**Prof. Dr. Christopher M. Bland**

College of Pharmacy, University  
of Georgia, Savannah, GA 31405,  
USA

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

The increase in *Clostridioides difficile* infection (CDI) cases during the past 2 decades has played a major role in the advancement of antimicrobial stewardship programs. CDI rates are often the focus of many antimicrobial- and syndrome-specific interventions deployed by ASPs. However, despite ASP and infection control efforts, CDI remains a problematic, opportunistic infection. Recent guideline updates from leading national and international expert panels have occurred with the advent of new therapeutics and evolving data. This Special Issue will seek manuscripts on ASP interventions that may impact CDI, therapeutic approaches to CDI, and additional healthcare-related research on CDI management including education, access, and more.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi